by McDermott + Bull | Sep 21, 2026 | Article, Ken Dropiewski, Ken Dropiewski Article
Most CEOs I work with are exceptional at vision. They can articulate where the company is going, why it matters, and what winning looks like. What they struggle to articulate is why they’re still approving vendor contracts, resolving team conflicts, and sitting...
by McDermott + Bull | May 19, 2026 | Article, Ken Dropiewski, Ken Dropiewski Article
The best candidates aren’t waiting for you. That’s the part most hiring teams miss. When a high-performing executive decides to explore their next opportunity, they don’t explore just yours. They explore the market — and the company that moves with...
by McDermott + Bull | Mar 20, 2026 | Article, Ken Dropiewski, Ken Dropiewski Article
Scaling a team isn’t about hiring faster or adding headcount. It’s about scaling clarity at the same pace as growth. Most companies don’t struggle because they can’t attract talent. They struggle because roles, expectations, and decision rights blur as the...
by McDermott + Bull | Nov 4, 2025 | Ken Dropiewski, Article, Ken Dropiewski Article
In today’s employment landscape, innovation alone isn’t enough to win the race for top talent. The most capable executives and emerging leaders aren’t just looking for another job — they’re searching for a mission worth committing to. They want to see substance behind...
by McDermott + Bull | Nov 27, 2024 | Ken Dropiewski, Article, Healthcare + Life Sciences, Healthcare + Life Sciences Article, Ken Dropiewski Article
What a difference a year makes. In the first half of 2024, the MedTech sector showed a notable uptick in M&A activity, with 114 acquisitions valued at $40.3 billion — close to last year’s total. Despite fewer venture rounds, funding remained strong at $9.7...
by McDermott + Bull | Jun 25, 2024 | Healthcare + Life Sciences, Healthcare + Life Sciences Article, Ken Dropiewski, Ken Dropiewski Article, Technology Article
The JPM Q1 2024 MedTech Licensing and Venture report highlights the first quarter of 2024 and shows promising developments in the MedTech investment landscape. There are indications of a potential recovery and growth compared to previous years. Can we be so lucky?...
